供体来源游离DNA监测用于肾移植后抗体介导排斥早期诊断的随机试验
本研究为单中心开放标签随机临床试验,纳入40例存在新发供体特异性抗HLA抗体且eGFR≥20 mL/min/1.73 m2的肾移植受者,随机分为dd-cfDNA引导活检组与临床引导活检组。
要点
- dd-cfDNA引导活检可缩短dnDSA阳性肾移植受者AMR诊断时间。
- 纵向dd-cfDNA监测对AMR的阳性预测值77%、阴性预测值85%。
- dd-cfDNA>50 copies/mL作为干预组活检触发阈值。
核心结论
- 在存在新发供体特异性抗HLA抗体的肾移植受者中,dd-cfDNA引导活检可缩短抗体介导排斥的诊断时间,从而加速治疗启动。
研究设计与样本
- 诊断性、单中心、开放标签、随机临床试验,纳入40例存在dnDSA且eGFR≥20 mL/min/1.73 m2、无既往活检证实的AMR的肾移植受者。
- 随机分为dd-cfDNA引导活检组(干预组)与临床引导活检组(对照组),观察12个月。
- 两组均在入组时及1、3、6、9、12个月评估dd-cfDNA;干预组dd-cfDNA>50 copies/mL时进行活检。
- 主要终点为从入组至诊断活动性或慢性活动性AMR的时间。
主要发现
- 纵向dd-cfDNA监测对AMR的阳性预测值为77%,阴性预测值为85%。
关键数值与推荐
- 干预组dd-cfDNA>50 copies/mL提示需进行活检。
- 纳入标准包括存在dnDSA且eGFR≥20 mL/min/1.73 m2。
- 主要终点为入组至诊断活动性或慢性活动性AMR的时间。
临床怎么用
- 对存在dnDSA的肾移植受者可考虑纵向监测dd-cfDNA,以早期发现AMR。
- dd-cfDNA升高(>50 copies/mL)时可触发活检以缩短AMR诊断时间。
局限性
- 单中心、开放标签设计,样本量较小(40例)。
- 研究纳入存在dnDSA且eGFR≥20 mL/min/1.73 m2的特定人群,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring need to be established. Early diagnosis of AMR at potentially reversible stages may be increasingly important due to emerging treatment options for AMR. We hypothesized that monitoring dd-cfDNA in KTR with de novo donor-specific anti-HLA antibodies (dnDSA) and performing kidney biopsy in case of increased dd-cfDNA may reduce time to AMR diagnosis in comparison with clinical indication biopsy. METHODS: In this diagnostic, single-center, open-label, randomized clinical trial, we assigned 40 KTR with prevalent dnDSA and estimated glomerular filtration rate ≥20 mL/min/1.73 m2, but without previous biopsy-proven AMR, to either dd-cfDNA-guided biopsy (intervention group) or clinician-guided biopsy (control group) over a 12-month period. In both groups, dd-cfDNA was assessed at inclusion and 1, 3, 6, 9 and 12 months. In the intervention group, dd-cfDNA >50 copies/mL indicated a biopsy. Biopsies for clinical indication could be performed at any point during the study period in both groups. A protocol biopsy was scheduled after 12 months for patients without dd-cfDNA-guided biopsy or clinical indication biopsy until study completion. The primary endpoint was time from study inclusion to diagnosis of active or chronic active AMR. RESULTS: Thirty-nine of 40 patients had functioning grafts at study completion. From these, 26 patients underwent biopsy, 13 in each group. AMR was diagnosed earlier in the intervention group than in the control group [median 2.8 months, interquartile range (IQR) 1.7-5.3 vs median 14.5 months, IQR 13.3-16.7, P = .003]. Longitudinal dd-cfDNA monitoring had 77% positive predictive value and 85% negative predictive value for AMR. CONCLUSIONS: Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and hereby expedite therapy initiation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04897438.
引用
- Akifova A, Budde K, Amann K, et al. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial. Nephrol Dial Transplant. 2025. PMID: 39673311. doi:10.1093/ndt/gfae282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。